Concepta PLC Board Changes (1891T)
November 13 2019 - 2:01AM
UK Regulatory
TIDMCPT
RNS Number : 1891T
Concepta PLC
13 November 2019
Concepta PLC
("Concepta" or the "Company")
Board Changes
Concepta PLC (AIM: CPT), the innovative UK personalised
healthcare company and developer of the proprietary self-test
platform ("myLotus(R)") the most accurate home-use fertility
tracking and pregnancy testing system available on the U.K. market,
announces that Matthew Walls, Chairman will step down with
immediate effect, by mutual agreement.
Non-Executive Director Adam Reynolds will take on the role as
Non-Executive Chairman with immediate effect. The Company has
identified, and is in the final stages of appointing a highly
experienced Chief Executive and additional Non-Executive Director,
each with a distinguished track record in women's fertility and
healthcare.
A further announcement will be made shortly once the Company's
NOMAD has completed all regulatory due diligence required for their
appointments.
Adam Reynolds commented: "I would like to thank Matthew for his
efforts over the past 18 months, during this period the Company has
achieved a number of key milestones including the first birth from
the myLotus product.
The Company is poised to announce a number of further births in
the coming months and the new management team which will be
announced shortly will take us through the next phase of
growth."
Enquiries:
Concepta plc www.conceptaplc.com
Adam Reynolds, Non-Executive Chairman Mob: +44 (0)7785 908 158
SPARK Advisory Partners Limited Tel: +44 (0)20 368 3550
(NOMAD)
Neil Baldwin / Mark Brady
Novum Securities (Broker) Tel: +44 (0)20 7399 9400
Colin Rowbury
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780
Relations)
Paul McManus lifesciences@walbrookpr.com
About Concepta PLC (www.conceptaplc.com)
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalized mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2019.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOADBBDBRBBBGCD
(END) Dow Jones Newswires
November 13, 2019 02:01 ET (07:01 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2023 to Apr 2024
